Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

See the latest Merck & Co Inc stock price (MRK:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Merck & Co., Inc. (NYSE:MRK) is one of Best Dividend Stocks to Buy for Dependable Growth. Merck & Co., Inc. (NYSE:MRK) is one ...

Read about Merck & Co Inc (MRK:XNYS) stock and today's latest news and financial updates. ... Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...